Login / Signup

Brentuximab vedotin in the treatment of relapsed/refractory CD30+ peripheral T-cell lymphoma: A FIL phase 2 study.

Vittorio StefoniCinzia PellegriniLisa ArgnaniPaolo CorradiniAnna DoderoLorella OrsucciStefano VolpettiPier Luigi Luigi Zinzani
Published in: Hematological oncology (2022)
Keyphrases
  • hodgkin lymphoma
  • acute lymphoblastic leukemia
  • acute myeloid leukemia
  • diffuse large b cell lymphoma
  • open label
  • multiple myeloma
  • combination therapy
  • double blind
  • nk cells
  • placebo controlled
  • smoking cessation